Controversies of dopamine agonists: Somnolence, cardiac valvulopathy and repetitive behaviors

Current Drug Therapy

Volumn 2, Issue 1, 2007, Pages 17-20

  Jain, Samay ^a,b   Waters, Cheryl H ^c  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Adverse effects; Dopamine agonists; Dopamine dysregulation syndrome; Punding; Sleep attacks; Valvulopathy

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; ERGOTAMINE; FENFLURAMINE; LEVODOPA; LISURIDE; METHYSERGIDE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE;

COMBINATION CHEMOTHERAPY; COMPULSION; DAYTIME SOMNOLENCE; DOPAMINERGIC SYSTEM; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EATING DISORDER; HUMAN; HYPERSEXUALITY; LEG SWELLING; LUNG FIBROSIS; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; VALVULAR HEART DISEASE; YAWNING;

EID: 34248221738     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488507779422347     Document Type: Review

References (19)

1. Stocchi F, Vacca L, Onofrj M. Are there Clinically Significant Differences between Dopamine Agonists. Adv Neurol 2003; 91: 259-266.
2. Waters C. Diagnosis and Management of Parkinson's disease. Fourth Edition ed: Professional Communications, Inc., 2005.
3. Horowski R, Jahnichen S, Pertz HH. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 2004; 19(12): 1523-1524.
4. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003; 16 Suppl 1: S13-19.
5. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52(9): 1908-1910.
6. Homann CN, Wenzel Y, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324: 1483-1487.
7. Plowman BK, Boggie DT, Morreale AP, Schaefer MG, Delattre ML, Chan H. Sleep attacks in patients receiving dopamine-receptor agonists. Am J Health Syst Pharm 2005; 62(5): 537-540.
8. Schafer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol 2000; 247 Suppl 4: IV/24-27.
9. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19(6): 656-662.
10. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363(9416): 1179-1183.
11. Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004; 19(12): 1522-1523.
12. Dhawan V, Medcalf P, Stegie F, et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm 2005; 112(5): 661-668.
13. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19(4): 397-405.
14. Voon V. Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord 2004; 19(4): 367-370.
15. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004; 17(4): 393-398.
16. Bearn J, Evans A, Kelleher M, Turner K, Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004; 76(3): 305-310.
17. Hall GW, Carriero NJ, Takushi RY, Montoya ID, Preston KL, Gorelick DA. Pathological gambling among cocaine-dependent outpatients. Am J Psychiatry 2000; 157(7): 1127-1133.
18. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19(4):433-437.
19. Nirenberg M, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21(4): 524-529.